Loading
CAR-T Cell Therapy Research / CRISPR and Genetic Engineering · Journal article
Gene Therapy · July 29, 2026
Early or partial results. Treat as a signal, not a conclusion.
This multi-site study validates two in vitro assays (SACF and GILA) for detecting CRISPR/Cas9-induced transformation in a MCF10A-PTPN12 knockout model, demonstrating reproducible limit of detection at 0.8% across four laboratories. The assays show promise as development-stage tools but remain in vitro surrogates that do not directly measure tumorigenicity in vivo; their clinical utility for actual gene therapy safety assessment remains to be established.
Multi-site prospective assay validation study. MCF10A mammary epithelial cells engineered with CRISPR/Cas9-mediated PTPN12 knockout; cells spiked at varying concentrations into wild-type MCF10A background. Intervention: SACF (Soft Agar Colony Formation) and GILA (Growth in Low Attachment) in vitro transformation assays. Compared with: Performance comparison between SACF and GILA assays across multiple sites. Four laboratories (specific locations not stated).
Both assays demonstrated consistent limit of detection (LOD) of 0.8% at most sites SACF showed broader dynamic range and stronger inter-laboratory correlation than GILA GILA exhibited weaker correlation due to plateauing at high spike-in concentrations (>12.5%)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These assays may support regulatory submissions for CRISPR/Cas9 gene therapies by providing standardized, reproducible in vitro transformation screening; however, they remain surrogate markers and do not replace in vivo tumorigenicity models or long-term clinical follow-up to establish actual safety in patients.
Multi-site assay validation study establishing reproducibility of in vitro transformation assays in a single cell line model; supports exploratory use but does not yet establish clinical utility or predict in vivo tumorigenicity risk in actual CRISPR therapies.
As stated by the source record.
Quoted from the source exactly as published.
These assays may support regulatory submissions for CRISPR/Cas9 gene therapies by providing standardized, reproducible in vitro transformation screening; however, they remain surrogate markers and do not replace in vivo tumorigenicity models or long-term clinical follow-up to establish actual safety in patients.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Tumorigenicity is a key safety concern for CRISPR/Cas9-based gene therapies, yet its assessment remains challenging due to the lack of relevant and sensitive in vivo models. This HESI Global multi-site study evaluated the Soft Agar Colony Formation (SACF) assay and the Growth in Low Attachment (GILA) assay for in vitro transformation testing of CRISPR/Cas9-edited cells as part of tumorigenicity risk assessment. Across four laboratories, MCF10A cells were spiked with varying concentrations of cells carrying a CRISPR/Cas9-mediated knockout of the known tumor suppressor PTPN12 to determine the assays' limit of detection (LOD), robustness and reproducibility. Both assays demonstrated a consistent LOD of 0.8% at most sites, with SACF showing a broader dynamic range and slightly stronger correlation across laboratories. GILA exhibited weaker correlation due to plateauing at high spike-in concentrations (>12.5%), and excluding these conditions improved inter-laboratory correlations. Additionally, the study identified key determinants of assay success, including the selection of appropriate cell lines and lots, and ensuring sufficient recovery time post-thaw. Together, these data establish multi-site reproducibility of SACF and GILA in the MCF10A-PTPN12 model evaluated here and support their use as animal-free, development-stage characterization tools contributing to tumorigenicity evidence generation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.